Traws Pharma shares jump 10.33% intraday after completing Phase 2 ratutrelvir trial with positive results and advancing tivoxavir marboxil flu prophylaxis plans.

Traws Pharma surged 10.33% intraday following the announcement of positive Phase 2 clinical results for ratutrelvir, its experimental oral COVID-19 treatment. The trial demonstrated a favorable safety profile with fewer adverse events, no viral rebounds, and faster symptom resolution compared to PAXLOVID, particularly in patients ineligible for ritonavir-based therapies. The company also highlighted plans to advance tivoxavir marboxil as a once-monthly influenza prophylactic, with a human challenge study scheduled for June 2026. These updates underscored Traws Pharma’s progress in developing differentiated antiviral therapies, addressing unmet medical needs in both acute respiratory viral diseases and long-term complications like Long COVID. The news directly aligned with the stock’s sharp intraday rally, reflecting investor optimism about the company’s pipeline advancements and potential market opportunities.